This publication provides comprehensive multidisciplinary guidance to promote standardized, effective and safe implementation of best practices for treating neuroendocrine and gastroenteropancreatic tumours through applying peptide receptor radionuclide therapy (PRRNT). Taking into account the latest international classifications of neuroendocrine tumours, both PRRNT as a sole treatment and as a treatment in combination with other options are considered. Comprehensive protocols for employing either yttrium-90 or lutetium-177 tagged somatostatin receptor targeting peptides and clinically tested protocols for renal protection are presented. The publication comprises a comprehensive compilation of medical evidence and experience. Furthermore, it contains clinical presentations, eligibility criteria and means of assessing the effectiveness of therapy utilizing molecular and morphological medical imaging techniques. The publication is a practical reference for specialists in clinical oncology and in nuclear medicine deploying and executing a comprehensive programme for treating patients with neuroendocrine tumours.